Theravance Biopharma R&d Ip, LLC

Christina Owens

Adam D Hughes

Steven D E Sullivan

Jennifer Kozak

Svitlana Kulyk

Paul Allegretti

Robert Murray McKinnell

Cameron Smith

Erik Fenster

Mandy Loo

Tom M Lam

Gabrielle Elaine Dolgonos

Philip Gerken

Provided herein are compounds of formula (I): and pharmaceutically-acceptable salts thereof, where A, W, X, Y and Z are defined in the specification. The compounds of formula (I) and pharmaceutically-acceptable salts thereof are Janus kinase (JAK) inhibitors. Also provided herein are pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat, e.g., inflammatory and fibrotic diseases, including respiratory diseases.

Imidazolo indazole compounds as JAK inhibitors

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

ALK5 inhibitors

Substituted pyridines and methods of use

Growing community of inventors

South San Francisco, CA, United States of America

Christina Owens